Kyowa Kirin drops development of entinostat (KHK2375)

8 October 2021

Japanese drugmaker Kyowa (TYO: 4151) has announced it is discontinuing the development of KHK2375 (generic name: entinostat).

KHK2375 is a Class I selective histone deacetylase (HDAC) inhibitor, which was discovered by Syndax Pharmaceuticals Inc. Kyowa Kirin signed a license agreement with the USA’s Syndax Pharmaceuticals (Nasdaq: SNDX) for the exclusive rights to the development and commercialization of KHK2375 in Japan and Korea in 2014.

Under the license agreement, Kyowa Kirin developed KHK2375 for indications of breast cancer in its territory. However, concerning the situation carefully, Kyowa Kirin discontinued KHK2375 development project. Kyowa Kirin paid an upfront $25 million for rights to the compound with a commitment to pay up to $75 million in milestones

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK